Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study

Figure 1 A 41-year-old woman with a palpable mass in right breast was diagnosed with ductal carcinoma in situ using ultrasound guided core-needle biopsy. MRI shows a 30-mm enhanced mass in the right breast (A, arrow). [F-18] FDG PET/CT also shows a mass with intense [F-18] FDG uptake (B and C, arrow). On histopathologic examination, a 32-mm DCIS (absence of comedo necrosis, ER positive, PgR positive, HER-2 positive, nuclear grade1) was found. MRI: Magnetic resonance imaging; FDG PET/CT: Fluorodeoxyglucose-positron emission tomography/computed tomography; DCIS: Ductal carcinoma in situ; ER: Estrogen receptor; PgR: Progesterone receptor; HER: Human epidermal growth factor receptor.

Figure 2 A 64-year-old woman with mammographically detected microcalcifications in right breast was diagnosed with ductal carcinoma in situ using stereotactic stereotactic vacuum-assisted biopsy. MRI shows a 12-mm non mass enhancement in the right breast (A, arrow). [F-18] FDG PET/CT did not depict any abnormal uptake (B and C). On histopathologic examination, a 15-mm DCIS (absence of comedo necrosis, ER positive, PgR positive, HER-2 positive, nuclear grade1 DCIS) was found. MRI: Magnetic resonance imaging; FDG PET/CT: Fluorodeoxyglucose-positron emission tomography/computed tomography; DCIS: Ductal carcinoma in situ; ER: Estrogen receptor; PgR: Progesterone receptor; HER: Human epidermal growth factor receptor.